DCT

2:24-cv-08435

American Regent Inc v. Cipla USA Inc

Log In
Key Events
Amended Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 2:24-cv-08435, D.N.J., 01/09/2025
  • Venue Allegations: Venue is alleged to be proper in the District of New Jersey because Defendant Cipla USA, Inc. resides in the district, maintains a regular and established place of business there, and has committed acts of infringement in New Jersey.
  • Core Dispute: Plaintiff alleges that Defendants' filing of an Abbreviated New Drug Application (ANDA) to market a generic version of Plaintiff's Tralement® product constitutes an act of infringement of five U.S. patents related to trace element compositions for parenteral nutrition.
  • Technical Context: The technology concerns stable, injectable compositions of essential trace elements (zinc, copper, manganese, selenium) used to supplement parenteral nutrition for patients who cannot receive oral or enteral feeding.
  • Key Procedural History: The lawsuit was initiated under the Hatch-Waxman Act following Defendants' submission of ANDA No. 218660, which included a Paragraph IV Certification asserting that the patents-in-suit are either invalid or will not be infringed by the proposed generic product.

Case Timeline

Date Event
2020-07-02 FDA approves Plaintiff's Tralement® New Drug Application (NDA)
2020-07-02 Earliest Priority Date for all Patents-in-Suit
2023-10-17 U.S. Patent No. 11,786,548 ('548) issues
2024-05-07 U.S. Patent No. 11,975,022 ('022) issues
2024-06-04 U.S. Patent No. 11,998,565 ('565) issues
2024-07-24 Defendants send Paragraph IV Notice Letter to Plaintiff
2024-11-26 U.S. Patent No. 12,150,956 ('956) issues
2024-11-26 U.S. Patent No. 12,150,957 ('957) issues
2024-12-19 Defendants consent to the filing of the Amended Complaint
2025-01-09 Amended Complaint filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 11,786,548 - "Trace element compositions, methods of making and use"

The Invention Explained

  • Problem Addressed: The patent background describes the short stability period (typically 24-48 hours) of parenteral nutrition admixtures once trace elements are added US 11,786,548 B2, col. 2:5-18 This short window leads to waste, increased costs, and logistical burdens for healthcare providers and patients, as admixtures must be prepared frequently and on a daily basis US 11,786,548 B2, col. 2:18-29
  • The Patented Solution: The invention is a stable, injectable trace element composition containing specific concentrations of zinc, copper, selenium, and manganese that, when added to parenteral nutrition, allows the resulting admixture to remain stable for a longer period US 11,786,548 B2, col. 2:46-54 This extended stability is intended to reduce the frequency of admixing, decrease costs, and improve quality of life for patients and caregivers US 11,786,548 B2, col. 2:30-38
  • Technical Importance: By creating a formulation that extends the stability of a parenteral nutrition admixture, the invention allows for preparation in larger batches, reducing waste and the logistical complexity of daily admixing for chronic care patients US 11,786,548 B2, col. 2:39-44

Key Claims at a Glance

  • The complaint brings an infringement action on the '548 patent generally, without specifying claims Compl. ¶¶50-52 Claim 1 is the first independent claim.
  • The essential elements of independent claim 1 are:
    • An injectable composition comprising water,
    • about 60 µg of selenium,
    • 3,000 µg of zinc,
    • about 300 µg of copper, and
    • about 55 µg of manganese per 1 mL of the injectable composition,
    • wherein the injectable composition contains 0 µg per 1 mL to about 10 µg per 1 mL of iron,
    • does not contain any vitamins,
    • contains no added chromium and
    • no aluminum or aluminum in an amount not to exceed 6 µg per 1 mL.
  • The complaint does not explicitly reserve the right to assert dependent claims for this patent, but this is standard practice.

U.S. Patent No. 11,975,022 - "Trace element compositions, methods of making and use"

The Invention Explained

  • Problem Addressed: The '022 Patent addresses the same technical problem as its parent '548 Patent: the limited stability of parenteral nutrition solutions after the addition of essential trace elements, which necessitates frequent and costly admixing US 11,975,022 B2, col. 1:62-67 US 11,975,022 B2, col. 2:5-18
  • The Patented Solution: The '022 Patent claims a method of providing trace elements to a patient by administering an injectable composition with the same specific concentrations of zinc, copper, selenium, and manganese as described in the '548 Patent US11975022B2, abstract This shifts the focus from the composition itself to the act of using it for patient treatment.
  • Technical Importance: The method claims provide a different scope of protection, covering the therapeutic use of the specified formulation, which is a key activity in the context of ANDA litigation where infringement is often based on the instructions for use in a proposed drug label.

Key Claims at a Glance

  • The complaint asserts the '022 patent generally, without specifying claims Compl. ¶¶57-59 Claim 1 is the first independent claim.
  • The essential elements of independent claim 1 are:
    • A method of providing trace elements to a patient in need thereof,
    • the method comprising administering an injectable trace element composition to the patient,
    • the composition comprising water, about 60 µg of selenium, about 3,000 µg of zinc, about 300 µg of copper, and about 55 µg of manganese per 1 mL,
    • wherein the composition contains 0 µg to about 10 µg of iron per 1 mL,
    • does not contain any vitamins,
    • contains no added chromium, and
    • no aluminum or aluminum in an amount not to exceed 6 µg per 1 mL.
  • The complaint does not explicitly reserve the right to assert dependent claims for this patent.

U.S. Patent No. 11,998,565 - "Trace element compositions, methods of making and use"

  • Technology Synopsis: The '565 patent relates to injectable trace element compositions for parenteral nutrition Compl. ¶64 The claims of this patent, which is in the same family as the '548 and '022 patents, are directed to compositions containing selenium and also including fluoride as an element, while containing no added chromium US11998565B2, claim 1
  • Asserted Claims: The complaint asserts the '565 patent generally Compl. ¶¶64-66 Claim 1 is a representative independent claim.
  • Accused Features: The accused features are the formulation and proposed use of the Defendants' ANDA Product Compl. ¶¶65-66

U.S. Patent No. 12,150,956 - "Trace element compositions, methods of making and use"

  • Technology Synopsis: The '956 patent relates to methods of using injectable trace element compositions for parenteral nutrition Compl. ¶71 As a continuation of the '565 patent, its claims are directed to methods of administering compositions containing selenium and fluoride, with no added chromium US12150956B2, claim 1
  • Asserted Claims: The complaint asserts the '956 patent generally Compl. ¶¶71-73 Claim 1 is a representative independent claim.
  • Accused Features: The accused features are the formulation and proposed use of the Defendants' ANDA Product Compl. ¶¶72-73

U.S. Patent No. 12,150,957 - "Trace element compositions, methods of making and use"

  • Technology Synopsis: The '957 patent relates to methods of using injectable trace element compositions for parenteral nutrition Compl. ¶77 This patent is also in the same family and claims methods of administering compositions containing selenium and iodine, with no added chromium US12150957B2, claim 1
  • Asserted Claims: The complaint asserts the '957 patent generally Compl. ¶¶77-79 Claim 1 is a representative independent claim.
  • Accused Features: The accused features are the formulation and proposed use of the Defendants' ANDA Product Compl. ¶¶78-79

III. The Accused Instrumentality

Product Identification

  • The accused instrumentality is Defendants' "ANDA Product," a generic version of Plaintiff's Tralement® (trace elements injection 4*, USP) in 1 mL single-dose vials, for which Defendants seek FDA approval via ANDA No. 218660 Compl. ¶1 Compl. ¶46

Functionality and Market Context

  • The complaint alleges that the ANDA Product is a drug product containing a combination of trace elements intended for parenteral nutrition Compl. ¶25 Compl. ¶45
  • The formulation of the ANDA Product is disclosed as containing 3 mg Zn/mL, 0.3 mg Cu/mL, 55 mcg Mn/mL, and 60 mcg Se/mL Compl. ¶46 This formulation is alleged to contain the same or equivalent ingredients in the same or equivalent amounts as Plaintiff's Tralement® product (Compl. ¶45; Compl. ¶47).
  • The complaint alleges the ANDA Product is intended for administration to patients by medical practitioners and will have the same or equivalent chemical and therapeutic properties as Tralement® (Compl. ¶48; Compl. ¶51).

IV. Analysis of Infringement Allegations

No probative visual evidence provided in complaint.

'548 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
An injectable composition comprising water, The ANDA Product is an injectable solution Compl. ¶46 ¶46 col. 11:13-14
about 60 µg of selenium, The ANDA Product contains 60 mcg Se/mL Compl. ¶46 ¶46 col. 11:13-24
3,000 µg of zinc, The ANDA Product contains 3 mg Zn/mL, which is equivalent to 3,000 µg/mL Compl. ¶46 ¶46 col. 11:13-24
about 300 µg of copper, and The ANDA Product contains 0.3 mg Cu/mL, which is equivalent to 300 µg/mL Compl. ¶46 ¶46 col. 11:13-24
about 55 µg of manganese per 1 mL of the injectable composition, The ANDA Product contains 55 mcg Mn/mL Compl. ¶46 ¶46 col. 11:13-24
wherein the injectable composition ... contains no added chromium The complaint alleges the ANDA Product will infringe claims which require "no added chromium" (Compl. ¶51; '548 Patent, claim 1). ¶51 col. 13:49-65

'022 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method of providing trace elements to a patient in need thereof, the method comprising administering an injectable trace element composition to the patient, The complaint alleges the ANDA Product will be administered to patients by medical practitioners according to the instructions in the proposed package insert Compl. ¶58 ¶58 col. 1:10-15
the composition comprising water, about 60 µg of selenium, about 3,000 µg of zinc, about 300 µg of copper, and about 55 µg of manganese per 1 mL, The ANDA Product's disclosed formulation contains 60 mcg Se/mL, 3 mg Zn/mL, 0.3 mg Cu/mL, and 55 mcg Mn/mL Compl. ¶46 ¶46 col. 1:17-26
wherein the composition ... does not contain any vitamins, The complaint alleges infringement of claims requiring the composition to not contain any vitamins ('022 Patent, claim 1). ¶58 col. 1:17-26
contains no added chromium The complaint alleges infringement of claims requiring the composition to contain no added chromium ('022 Patent, claim 1). ¶58 col. 1:17-26

Identified Points of Contention

  • Literal Infringement: The formulation of the ANDA Product, as disclosed in the complaint Compl. ¶46, corresponds exactly to the concentrations of the four primary trace elements recited in claim 1 of the '548 and '022 patents. This raises the question of whether Defendants will contest literal infringement or focus on invalidity arguments.
  • Scope of "about": The '548 and '022 patents use the term "about" for the concentrations of selenium, copper, and manganese, but not for zinc. The court may need to determine if standard manufacturing variances for the ANDA product fall within the scope of "about" and whether the precise 3,000 µg/mL of zinc constitutes literal infringement.
  • Negative Limitations: The claims in the '548 and '022 patents include several negative limitations (e.g., "no added chromium," "does not contain any vitamins," and specific limits on iron and aluminum). A key factual question will be whether the ANDA Product's final formulation, including any excipients or impurities, meets these negative requirements.

V. Key Claim Terms for Construction

  • The Term: "about"

  • Context and Importance: This term modifies the recited concentrations of selenium, copper, and manganese in the independent claims of the '548 and '022 patents. Its construction is critical because it defines the permissible range of deviation from the stated values. The infringement analysis may turn on whether the actual concentrations in the Defendants' ANDA Product, accounting for manufacturing tolerances, fall within the scope of the claimed amounts.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The specification uses "about" consistently when describing the concentration ranges of the trace elements, suggesting an intent to encompass normal variations and not be limited to the exact numerical values (US10 B2, col. 2:65-68).
    • Evidence for a Narrower Interpretation: The patent explicitly recites "3,000 µg of zinc" without the modifier "about," while using "about" for other elements in the same claim US 11,786,548 B2, claim 1 This differentiation may suggest that when "about" is used, it implies a narrow range of equivalents, and when it is absent, the value is intended to be precise.

  • The Term: "no added chromium"

  • Context and Importance: This is a negative limitation in the independent claims of the '548 and '022 patents. Its construction will be central to determining infringement, as the dispute may focus on whether trace amounts of chromium present as impurities in the raw materials or leached from manufacturing equipment fall within the scope of the prohibition.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: A defendant may argue that "no added chromium" means no chromium is intentionally included as an active ingredient, and that unavoidable impurities do not constitute "added" chromium. The specification discusses adjusting for "contaminants that may already be present in the parenteral nutrition," which could be argued to distinguish between intentional additives and background impurities US 11,786,548 B2, col. 2:4-8
    • Evidence for a Narrower Interpretation: The plaintiff may argue that the term means the final composition is essentially free of chromium, regardless of the source. The specification notes that in some instances, "daily doses of chromium are not typically needed," and the claims reflect this by explicitly excluding it, suggesting a deliberate choice to create a chromium-free formulation US 11,786,548 B2, col. 1:62-65 US 11,786,548 B2, col. 13:49-65

VI. Other Allegations

  • Indirect Infringement: The complaint alleges induced infringement on the basis that Defendants, upon information and belief, will instruct and encourage patients and medical practitioners to administer the ANDA Product according to the proposed package insert, which will direct the performance of the steps of the asserted method claims Compl. ¶51 Compl. ¶58 Contributory infringement is alleged on the basis that the ANDA Product is especially made or adapted for infringing the patents and is not suitable for substantial non-infringing use Compl. ¶52 Compl. ¶59
  • Willful Infringement: The complaint alleges that Defendants have had knowledge of the patents-in-suit since at least the date they submitted the ANDA with a Paragraph IV Certification Compl. ¶54 Compl. ¶61 Compl. ¶68 Compl. ¶75 Compl. ¶81 The complaint also seeks a finding that the case is "exceptional" and requests an award of attorneys' fees Compl. ¶55 Compl. ¶62 Compl. ¶69

VII. Analyst's Conclusion: Key Questions for the Case

  • A central issue will be one of compositional identity: Given that the Defendants' ANDA Product formulation, as alleged in the complaint, appears to precisely match the concentrations of the four key active ingredients in the '548 and '022 patents, will the primary dispute center on the interpretation and satisfaction of the claims' negative limitations, such as "no added chromium" and the specified limits on iron and aluminum?
  • A key evidentiary question will be one of infringing use: For the asserted method claims, what evidence will be presented to demonstrate that the proposed label for the ANDA Product will inevitably lead medical practitioners to "administer" the composition in a manner that directly infringes, thereby establishing the required elements for induced infringement?
  • A third question concerns the scope of later-issued patents: How will the court address the infringement allegations for the '956 and '957 patents, which issued after Defendants sent their Paragraph IV notice letter and after the initial complaint was filed, particularly regarding the elements of knowledge and intent for indirect infringement?
Loading Amended Complaint